GSK announces start of phase III programme for mepolizumab in patients with COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the start of a phase III programme to evaluate the efficacy and safety of mepolizumab as an adjunctive therapy for adults who have severe chronic obstructive pulmonary disease (COPD).
Source: GSK news - Category: Pharmaceuticals Source Type: news
More News: Chronic Obstructive Pulmonary | Pharmaceuticals